---
title: "Lysergide (DT120) in Generalized anxiety disorder: Heterogeneity of treatment effect"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Heterogeneity of treatment effect. Topics: Baseline severity and antidepressant efficacy in GAD: individual participant data, Age as a moderator of psychotherapy and medication effects, Older adults, DT120 in Voyage: change in HAM-A score at Week 12 by subgroup, and 8 further topics. 12 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Baseline severity and antidepressant efficacy in GAD: individual participant data

> “For GAD and PD, severity moderated antidepressant efficacy. The antidepressant–placebo difference was 1.4 (95% CI: 0.4–2.5; SMD: 0.21) Hamilton Anxiety Rating Scale (HAM‐A) points for participants with mild GAD (baseline HAM‐A = 10), increasing to 4.0 (3.4–4.6; SMD: 0.45) or greater for severely ill participants (HAM‐A ≥ 30).”
> “Half of the GAD trials specified a minimum HAM‐A score of 20, for instance, even though most primary care patients with GAD have scores below 20 (Rollman et al., 2005).”

Source: [de Vries et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6667912/)

<a id="topic-2.2.2.3-2"></a>

### Age as a moderator of psychotherapy and medication effects

> “Mean age of the sample was a significant moderator of psychotherapy outcomes. A lower mean age predicted a larger treatment effect size in psychotherapy (β = −0.013, p < 0.05).”
> “Mean age was not associated with outcome in medication studies (p > 0.05).”
> “There was no significant relationship between effect size and treatment dose (number of sessions or medication dosage), treatment quality, year of publication, fixed versus flexible dose, percent comorbidity, percent female, or pretreatment severity (all p > 0.10).”

Source: [Carl et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7063818/)

<a id="topic-2.2.2.3-3"></a>

### Older adults

> “Twenty-seven trials (14 pharmacological, 13 psychotherapeutic) fulfilled the inclusion criteria, reporting results from 2373 baseline participants.”
> “Pooled treatment effects for pharmacological (OR=0.32, 95% CI: 0.18, 0.54) and psychotherapeutic (OR=0.33, 95% CI: 0.17, 0.66) trials were similar, with findings in each case favoring active interventions over control conditions.”

Source: [Gonçalves and Byrne (2012)](https://pubmed.ncbi.nlm.nih.gov/21907538/)

<a id="topic-2.2.2.3-4"></a>

### DT120 in Voyage: change in HAM-A score at Week 12 by subgroup

| Subgroup | Placebo-adjusted LS mean change (SE) |
| --- | --- |
| All participants | “−5.4 (1.0)” |
| Time since GAD symptoms began, less than 22 years (n = 107) | “−5.9 (1.4)” |
| Time since GAD symptoms began, 22 years or more (n = 107) | “−4.7 (1.5)” |
| Previous GAD medications, fewer than 2 (n = 136) | “−4.2 (1.2)” |
| Previous GAD medications, 2 or more (n = 78) | “−5.6 (1.7)” |
| Male (n = 77) | “−7.1 (1.7)” |
| Female (n = 137) | “−5.5 (1.2)” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “The treatment effect was maintained across key subgroups, including in participants with ≥2 previous trials of medications for GAD (Figure 5)”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.2.2.3-5"></a>

### DT120 in Panorama: subgroups and stability of subgroup estimates

> “Treatment Effect Maintained Across Key Subgroups”
> “Including Those Failed by 2+ Prior Treatments”
> “Subgroup analysis of ITT population; 100 µg and placebo groups only.”
> “If the number of patients is small for a subgroup, the treatment difference will not be stable as it would be highly sensitive to outliers.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-2.2.2.3-6"></a>

### Dose and functional unblinding in Panorama

> “Week 4: 50% less separation at 50 µg”
> “Week 12: 29% less separation at 50 µg”
> “91% and 95% of participants at 50 and 100 µg correctly guessed assignment to drug”
> “Results support the conclusion that DT120 dose response is not attributable to functional unblinding”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-2.2.2.3-7"></a>

### Functional unblinding and dose in the phase 2b trial

> “All doses of MM120 produced transient perceptual, cognitive, and emotional effects leading to participant unblinding.”
> “Central rater blinding was preserved in more than 80% of HAM-A assessments,31 despite approximately 85% of participants correctly identifying assignment to active treatment.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.2.2.3-8"></a>

### Expectancy and blinding in psychedelic trials

> “While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.”
> “We suggest that psychedelic RCTs should routinely measure de-blinding and expectancy.”

Source: [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/)

<a id="topic-2.2.2.3-9"></a>

### Prior psychedelic exposure: FDA recommendation

> “enrolling individuals with prior psychedelic drug exposure raises the possibility of expectation bias given that participants who have prior experience with psychedelic drugs are more likely to recognize their subjective effects (i.e., leading to functional unblinding) and anticipate a treatment benefit.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.2.2.3-10"></a>

### Prior psychedelic exposure in the DT120 phase 3 trials

> “Exclusion criteria related to prior use of psychedelics was later amended to any lifetime use of psychedelics based on FDA feedback.”
> “Baseline expectancy was measured in participants, and perceived treatment was recorded for both participants and central raters”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

| Past psychedelic use in Voyage | DT120 ODT (n = 107) | Placebo ODT (n = 107) | Overall (N = 214) |
| --- | --- | --- | --- |
| Any psychedelic | “18 (17)” | “27 (25)” | “45 (21)” |
| LSD | “10 (9)” | “9 (8)” | “19 (9)” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.2.2.3-11"></a>

### Functional unblinding in a health technology assessment of another psychedelic treatment

> “Because of the effects of MDMA, the trials were, essentially, unblinded with nearly all patients who received MDMA correctly identifying that they were in the MDMA arm of the trials.”
> “As such, we conclude that the current publicly-available evidence for MDMA-AP is insufficient”

Source: [Mustafa et al. (2024)](https://icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf)

<a id="topic-2.2.2.3-12"></a>

### Company statement on heterogeneous populations

> “as we have shown now in GAD and MDD, we seem to be able to demonstrate efficacy across a range of heterogeneous populations.”

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
